Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 5, 2009, Pages 358-364

  Morales, N P ^a   Limenta, L M G ^a,d   Yamanont, P ^a   Jirasomprasert, T ^a   Wilairat, P ^a   Chantharaksri, U ^a   Chuncharunee, S ^b   Fucharoen, S ^c  

^a Mahidol University ^*  (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bioequivalence; Deferiprone; WHO criteria

Indexed keywords

DEFERIPRONE; GPO L ONE; UNCLASSIFIED DRUG; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY TEMPERATURE MONITORING; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; FILM COATING; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; THAILAND; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ADOLESCENT; COMPARATIVE STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; TABLET;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; MIDDLE AGED; PYRIDONES; TABLETS; THAILAND; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 67649450623     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47358     Document Type: Article

References (20)

1. Al-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995; 89: 403-408.
2. Balfour JAB and Foster R. Deferiprone: A review of its chinical potential in iron overload in β-thalassemia major and other transfusion-dependent diseases. Drugs. 1999; 58: 553-578.
3. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A. Survival and complication in thalassemia. Ann NY Aced Sic. 2005; 1054: 40-47.
4. Borgna-Pignatt, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine or deferiprone-treated patients with thalassemia major. Blood. 2006; 107: 3733-3737.
5. Chaston TB, Ridchardson DR. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity and toxicity. Am J Hematol. 2003; 73: 200-210.
6. CHMP efficacy working party therapeutic subgroup on pharmacokinetics (EWP-PK). Questions & answers on the bioavailability and bioequivalence guideline. In: European Medicines Agency. Evaluation of medicines for human use. London: Canary Wharf; 2006.
7. Cohen AR. New Advances in iron chelation therapy. Hematology Am Soc Hematol Educ program. 2006; 42-47.
8. Devanur LD, Neubert H, Hider RC. The Fenton activity of iron (III) in the presence of deferiprone. J Pharm Sci. 2008; 97: 1454-1467.
9. Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G. The pharmacokinetic and pharmocodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. Int J Clin Pharmacol Ther. 1996; 34: 288-292.
10. Kontogiorghes GJ, Goddard JG, Barlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydoxypyrid-4-one. Clin Pharmacol Ther. 1990; 48: 255-261.
11. Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. 2003; 26: 553-584.
12. Limenta LMG, Jirasomprasert T, Tankanitlert J, Svasti S, Wilairat P, Chantraraksri U, Fucharoen S, Morales NP. UGT1A6 genetype-related pharmacokinetics of deferiprone (L1) in healthy volunteers. Br J Clin Pharmacol. 2008; 65: 908-916.
13. Matsui D, Klein J, Hermann C, Grunau V, McClelland R, Chung D, St-Louis P, Olivieri N, Koren G. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydoxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther. 1991; 50: 294-298.
14. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. 2003; 88: 489-496.
15. Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Spiphen K, Thakernpol K, Atisuk K, Fucharoen S, Chantraluksri U, Shalev O, Hoffbrand V. Clinical trial of deferiprone iron chelation therapy in β-thalassemia/haemoglobin E patients in Thailand. Br J Haematol. 2003; 122: 305-310.
16. Singh S, Epemolu RO, Dobbin PS, Tilbrook GS, Ellis BL, Damani LA, Hider RC. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. Drug Metab Dispos. 1992; 20: 256-261.
17. Stobie S, Tyberg J, Matsui D, Fernandes D, Klein J, Olivieri N, Bentur Y, Koren G. Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydoxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients. In J Clin Pharmacol Ther Toxicol. 1993; 31: 602-605.
18. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Hematologica. 2006; 91: 1187-1192.
19. Wong C, Richardson DR. β-Thalassemia: emergence of new and improved iron chelators for treatment. In J Biochem Cell Biol. 2003; 35: 1144-1149.
20. World Health Organization. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. In: WHO Technical Report Series No. 937; 2006.